MAZE vs. LYEL
MAZE (Maze Therapeutics, Inc) and LYEL (Lyell Immunopharma, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past year, MAZE returned 83.13% vs -3.12% for LYEL. At a 0.22 correlation, their price movements are largely independent.
Performance
MAZE vs. LYEL - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, MAZE achieves a -38.69% return, which is significantly higher than LYEL's -57.60% return.
MAZE
- 1D
- 2.17%
- 1M
- -4.37%
- YTD
- -38.69%
- 6M
- -40.38%
- 1Y
- 83.13%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
LYEL
- 1D
- 3.82%
- 1M
- -36.71%
- YTD
- -57.60%
- 6M
- -48.74%
- 1Y
- -3.12%
- 3Y*
- -42.43%
- 5Y*
- —
- 10Y*
- —
MAZE vs. LYEL - Yearly Performance Comparison
| 2026 (YTD) | 2025 | |
|---|---|---|
MAZE Maze Therapeutics, Inc | -38.69% | 159.75% |
LYEL Lyell Immunopharma, Inc. | -57.60% | 160.71% |
Correlation
The correlation between MAZE and LYEL is 0.23, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.23 |
Correlation (All Time) Calculated using the full available price history since Feb 3, 2025 | 0.22 |
Fundamentals
MAZE:
$1.37B
LYEL:
$285.48M
MAZE:
-$2.63
LYEL:
-$13.68
MAZE:
4.01
LYEL:
1.04
MAZE:
$0.00
LYEL:
$31.00K
MAZE:
-$1.15M
LYEL:
-$11.51M
MAZE:
-$126.66M
LYEL:
-$140.21M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
MAZE vs. LYEL — Risk / Return Rank
MAZE
LYEL
MAZE vs. LYEL - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Maze Therapeutics, Inc (MAZE) and Lyell Immunopharma, Inc. (LYEL). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| MAZE | LYEL | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.97 | ||
| Sortino ratioReturn per unit of downside risk | +1.39 | ||
| Omega ratioGain probability vs. loss probability | 1.28 | 1.07 | +0.21 |
| Calmar ratioReturn relative to maximum drawdown | 1.57 | -0.05 | +1.62 |
| Martin ratioReturn relative to average drawdown | 3.60 | -0.10 | +3.70 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| MAZE | LYEL | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.93 | -0.04 | +0.97 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.44 | -0.51 | +0.95 |
Drawdowns
MAZE vs. LYEL - Drawdown Comparison
The maximum MAZE drawdown since its inception was -53.14%, smaller than the maximum LYEL drawdown of -97.83%. Use the drawdown chart below to compare losses from any high point for MAZE and LYEL.
Loading charts...
Drawdown Indicators
| MAZE | LYEL | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -53.14% | -97.83% | +44.69% |
Max Drawdown (1Y)Largest decline over 1 year | -53.14% | -67.44% | +14.30% |
Max Drawdown (3Y)Largest decline over 3 years | — | -89.90% | — |
Current DrawdownCurrent decline from peak | -51.00% | -96.36% | +45.36% |
Average DrawdownAverage peak-to-trough decline | -20.22% | -79.25% | +59.03% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 23.24% | 31.12% | -7.88% |
Volatility
MAZE vs. LYEL - Volatility Comparison
The current volatility for Maze Therapeutics, Inc (MAZE) is 12.34%, while Lyell Immunopharma, Inc. (LYEL) has a volatility of 25.94%. This indicates that MAZE experiences smaller price fluctuations and is considered to be less risky than LYEL based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| MAZE | LYEL | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 12.34% | 25.94% | -13.60% |
Volatility (6M)Calculated over the trailing 6-month period | 57.41% | 58.25% | -0.84% |
Volatility (1Y)Calculated over the trailing 1-year period | 89.51% | 109.22% | -19.71% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 95.02% | 94.48% | +0.54% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 95.02% | 94.48% | +0.54% |
Dividends
MAZE vs. LYEL - Dividend Comparison
Neither MAZE nor LYEL has paid dividends to shareholders.
Financials
MAZE vs. LYEL - Financials Comparison
This section allows you to compare key financial metrics between Maze Therapeutics, Inc and Lyell Immunopharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
MAZE and LYEL have a correlation of 0.23, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LYEL has higher volatility (25.94%) compared to MAZE (12.34%). In terms of maximum drawdown, MAZE dropped -53.14% vs LYEL's -97.83%.
MAZE currently has the higher Sharpe Ratio (0.93 vs -0.04), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for MAZE and LYEL
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer